Zevra Therapeutics (ZVRA) Projected to Post Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.96 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $7.87 on Friday. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $430.32 million, a P/E ratio of -3.99 and a beta of 1.87. The stock’s 50 day moving average is $7.52 and its 200 day moving average is $8.07.

Insider Buying and Selling

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at $231,759.96. This represents a 26.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ZVRA. JMP Securities set a $18.00 price target on Zevra Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and a consensus target price of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.